公开(公告)号：EP2988736A1

公开(公告)日：2016-03-02

申请号：EP13767126.9

申请日：2013-06-25

申请人： Cadila Healthcare Limited

发明人： PATEL, Pankaj ,  HARIPRASAD JANI, Rajendrakumar

IPC分类号： A61K31/00 ,  A61K31/40 ,  A61P1/16

CPC分类号： A61K31/40 ,  Y10S514/893

摘要： The present invention provides a compound of Formula (I) or pharmaceutical acceptable thereof, wherein ‘R’ is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (I) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (NAFLD) including fatty liver (steatosis), nonalcoholic steatohepatitis (NASH), and cirrhosis (advanced scarring of the liver).

摘要翻译： 本发明提供式（I）化合物或其药学上可接受的盐，其中“R”在本文中描述。 此外，本发明涉及包含有效治疗量的式（I）化合物和使用该化合物治疗或预防障碍的方法的组合物，例如非酒精性脂肪肝疾病（NAFLD），包括脂肪肝（脂肪变性），非酒精性脂肪性肝炎（NASH） ）和肝硬化（肝脏晚期瘢痕形成）。

公开(公告)号：EP2401253B1

公开(公告)日：2016-01-13

申请号：EP10719784.0

申请日：2010-01-25

申请人： Cadila Healthcare Limited

发明人： PANDEY, Bipin ,  DAVE, Mayank, Ghanshyambhai ,  SHAH, Mitesh

IPC分类号： C07D207/20 ,  C07D211/70 ,  C07D213/61

CPC分类号： C07D213/61 ,  C07D207/20 ,  C07D211/70

公开(公告)号：EP2899194A1

公开(公告)日：2015-07-29

申请号：EP14196602.8

申请日：2012-03-02

申请人： Cadila Healthcare Limited

发明人： Pandey, Bipin ,  Dave, Mayank Ghanshyambhai ,  Kothari, Himanshu M. ,  Shukla, Bhavin Shriprasad

IPC分类号： C07D487/04 ,  A61K31/4985 ,  A61P3/10

CPC分类号： C07D487/04

摘要： The present invention discloses an amorphous besylate salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine.and processes for its preparation and isolation.

摘要翻译： 本发明公开了（2R）-4-氧代-4- [3-（三氟甲基）-5,6-二氢[1,2,4]三唑并[4,3-a]吡嗪-7-酮的无定形苯磺酸盐 （8H） - 基] -1-（2,4,5-三氟苯基）丁-2-胺，其制备和分离方法。

公开(公告)号：EP2658851B1

公开(公告)日：2015-03-11

申请号：EP11818931.5

申请日：2011-12-26

申请人： Cadila Healthcare Limited

发明人： PINGALI, Harikishore ,  MAKADIA, Pankaj ,  PANDYA, Vrajesh ,  KALAPATAPU, V. V. M. Sairam ,  JAIN, Mukul R.

IPC分类号： C07D309/06 ,  C07D407/12 ,  C07D409/12 ,  C07D413/12 ,  A61K31/35 ,  A61P7/00

CPC分类号： C07D309/04 ,  A61K31/137 ,  A61K31/351 ,  A61K31/381 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/422 ,  A61K31/4433 ,  A61K31/4709 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/541 ,  A61K45/06 ,  C07D209/32 ,  C07D213/64 ,  C07D215/06 ,  C07D239/28 ,  C07D263/38 ,  C07D309/06 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12

公开(公告)号：EP2427201B1

公开(公告)日：2015-01-28

申请号：EP10747684.8

申请日：2010-05-03

申请人： Cadila Healthcare Limited

发明人： GLUECK, Reinhard ,  FAZIO, Agata ,  GIANINO, Viviana ,  BILLETER, Martin

IPC分类号： A61K35/76 ,  A61P33/06

CPC分类号： A61K39/165 ,  A61K35/13 ,  A61K38/2013 ,  A61K39/0015 ,  A61K39/015 ,  A61K39/12 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/55566 ,  A61K2039/55588 ,  A61K2039/575 ,  A61K2039/70 ,  C12N7/00 ,  C12N2760/18421 ,  C12N2760/18434 ,  C12N2760/18442 ,  C12N2760/18443 ,  Y02A50/412

摘要： The present invention relates to a combined measles-malaria vaccine containing different attenuated recombinant measles-malaria vectors comprising a heterologous nucleic acid encoding several Plasmodium falciparum antigens. Preferably, it relates to viral vectors that comprise nucleic acids encoding the circumsporozoite (CS) protein of P . falciparum, the merozoite surface protein 1 (MSP-I) of P. falciparum, and its derivatives (p-42; p-83-30-38) in its glycosylated and secreted forms, and apical membrane antigen 1 (AMA1) of P . falciparum, and its anchored or secreted form. The viral vector stems from an attenuated measles virus, based on a strain that is used as a vaccine and is efficient in delivering the gene of interest and that binds to and infects the relevant immune cells efficiently. In a preferred embodiment, the CS, the MSP1 and the AMA1 proteins are generated from the virus such that they will give rise to a potent immune response in mammals, preferably humans; the expression of the proteins is elevated due to human codon optimisation. Furthermore, the invention relates to the use of the recombinant vaccine in the prophylactic treatment of malaria.

公开(公告)号：EP1618111B1

公开(公告)日：2014-12-24

申请号：EP04770646.0

申请日：2004-04-22

申请人： CADILA HEALTHCARE LIMITED

发明人： LOHRAY, Braj, Bhushan Cadila Healthcare Limited ,  LOHRAY, Vidya, Bhushan Cadila Healthcare Limited ,  DAVE, Mayank, G. Cadila Healthcare Limited

IPC分类号： C07D495/04

CPC分类号： C07D495/04

公开(公告)号：EP2780327A1

公开(公告)日：2014-09-24

申请号：EP12839184.4

申请日：2012-11-12

申请人： Cadila Healthcare Limited

发明人： DWIVEDI, Shriprakash Dhar ,  PRASAD, Ashok ,  SHARMA, Mukul Hariprasad ,  SHARMA, Piyush Rajendra ,  PARIHAR, Jaiprakash Ajitsingh

IPC分类号： C07D223/16 ,  A61K31/55 ,  A61P9/06

CPC分类号： C07D223/16 ,  B65B7/02 ,  B65B31/00 ,  B65B61/20 ,  B65D31/02 ,  B65D31/04 ,  B65D81/266 ,  C07B2200/13 ,  C30B7/02 ,  C30B29/54 ,  Y10T428/2982

摘要： A storage stable crystalline Form II of ivabradine hydrochloride having characteristic X-ray powder diffraction peaks at about 15.50°, 18.02°, 19.00°, 19.80°, 22.42°, 24.16°, and 25.46°±0.2° (2¸); comprising a packaging which includes placing crystalline ivabradine hydrochloride in a non-permeable bag; placing the non-permeable bag in polyethylene bag, optionally containing oxygen busters and sealing it; placing the polyethylene bag in a triple laminated bag, optionally containing oxygen busters and sealing it; placing the triple laminated bag inside a high density polyethylene (HDPE) container and sealing it.

摘要翻译： 公开了伊伐布雷定盐酸盐的稳定结晶形式II和稳定结晶形式III及其制备方法。

公开(公告)号：EP2451786B1

公开(公告)日：2014-01-22

申请号：EP10779052.9

申请日：2010-07-12

申请人： Cadila Healthcare Limited

发明人： SATA, Kaushik, Babubhai ,  PANDEY, Bipin

IPC分类号： C07D239/34

CPC分类号： C07D239/34

公开(公告)号：EP2201120B1

公开(公告)日：2013-12-25

申请号：EP08852235.4

申请日：2008-09-22

申请人： Cadila Healthcare Limited

发明人： MENDIRETTA, Sanjeev, Kumar ,  PATEL, Pankaj, R. ,  BANDYOPADHYAY, Sanjay ,  SARASWAT, Vibhor ,  SINGH, Arun, Kumar

IPC分类号： C12N15/62

CPC分类号： C12N15/62 ,  C07K14/535 ,  C07K14/62 ,  C07K14/635 ,  C12P21/02

摘要： The present invention discloses an improved process for the production of desired recombinant peptides from bacterial cells by using G-CSF as a novel fusion partner for their high level expression in these cells. The invention further provides an expression system comprising the fusion protein wherein the G-CSF is operatively linked to the peptide of interest via an enzymatic or chemical cleavage site which can be used to separate the fusion partner from the said peptide.

公开(公告)号：EP2567957A1

公开(公告)日：2013-03-13

申请号：EP12195826.8

申请日：2010-09-29

申请人： CADILA HEALTHCARE LIMITED

发明人： Pingali, Harikishore ,  Kalapatapu, V., V., M., Sairam ,  Makadia, Pankaj ,  Jain, Mukul, R.

IPC分类号： C07D405/06 ,  C07D405/14 ,  C07D413/06 ,  C07D413/14 ,  C07D417/06 ,  C07D417/14 ,  A61K31/357 ,  A61P3/06

CPC分类号： C07D413/06 ,  C07D405/06 ,  C07D413/14 ,  C07D417/06 ,  C07D417/14

摘要： The present invention relates to compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation.

摘要翻译： 本发明涉及通式（I）的化合物，其互变异构形式，其立体异构体，其药学上可接受的盐，含有它们的药物组合物，其制备方法，这些化合物在医药中的用途以及参与其制备的中间体。